Clinical Trials Related to Syndax Pharmaceuticals

Related studies linked through entity extraction aliases.

Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye

Status: COMPLETED
Phase: PHASE2

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Status: COMPLETED
Phase: PHASE1/PHASE2

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

Status: WITHDRAWN
Phase: PHASE2

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Status: COMPLETED
Phase: PHASE2

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Status: COMPLETED
Phase: PHASE1

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Status: TERMINATED
Phase: PHASE2

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Status: TERMINATED
Phase: PHASE2

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Status: COMPLETED
Phase: PHASE2

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Status: TERMINATED
Phase: PHASE1

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Status: TERMINATED
Phase: PHASE2

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Status: COMPLETED
Phase: PHASE2

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Status: COMPLETED
Phase: PHASE1/PHASE2